TG Therapeutics, Inc. (TGTX)
56.01
+1.74
(+3.21%)
USD |
NASDAQ |
Aug 24, 16:00
56.45
+0.44
(+0.79%)
After-Hours: 20:00
TG Therapeutics Gross Profit Margin (Quarterly) : 82.86% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.86% |
| March 31, 2026 | 83.65% |
| December 31, 2025 | 80.19% |
| September 30, 2025 | 82.63% |
| June 30, 2025 | 86.58% |
| March 31, 2025 | 87.09% |
| December 31, 2024 | 85.71% |
| September 30, 2024 | 88.79% |
| June 30, 2024 | 88.60% |
| March 31, 2024 | 91.30% |
| December 31, 2023 | 81.93% |
| September 30, 2023 | 97.81% |
| June 30, 2023 | 87.58% |
| March 31, 2023 | 87.47% |
| December 31, 2022 | -61.25% |
| September 30, 2022 | -39.36% |
| June 30, 2022 | 74.07% |
| March 31, 2022 | 88.24% |
| December 31, 2021 | 90.95% |
| September 30, 2021 | 85.62% |
| June 30, 2021 | 90.42% |
| March 31, 2021 | 82.47% |
| December 31, 2020 | -178.9% |
| September 30, 2020 | -147.4% |
| June 30, 2020 | -136.8% |
| Date | Value |
|---|---|
| March 31, 2020 | -5.39K% |
| December 31, 2019 | -92.11% |
| September 30, 2019 | 31.58% |
| June 30, 2019 | 39.47% |
| March 31, 2019 | 39.47% |
| December 31, 2018 | 36.84% |
| September 30, 2018 | 39.47% |
| June 30, 2018 | 44.74% |
| March 31, 2018 | 47.37% |
| December 31, 2017 | 46.46% |
| September 30, 2017 | 45.14% |
| June 30, 2017 | 44.74% |
| March 31, 2017 | 47.37% |
| December 31, 2016 | 46.19% |
| September 30, 2016 | 49.87% |
| June 30, 2016 | 55.64% |
| March 31, 2016 | 83.20% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 93.46% |
| MAIA Biotechnology, Inc. | -- |
| Vericel Corp. | 72.82% |
| Incyte Corp. | 92.57% |
| Regeneron Pharmaceuticals, Inc. | 83.68% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 81.19% |
| Return on Assets | 37.04% |
| Return on Invested Capital | 44.26% |
| Profit Margin (Quarterly) | 3.24% |
| Operating Margin (Quarterly) | 9.02% |
| Return on Net Operating Assets | 94.58% |